Visomitin®

Biohacker Review: Free Radical Free Vision

I've been using Visomitin for 6 months now. I have problematic eyes, to say the least, I'm nearsighted and cross-eyed with some optic nerve damage so Lasik surgery is not a viable option for improving my vision.

I researched SKQ1 thoroughly before deciding to use Visomitin, which delivers a mitochondrially targeted antioxidant where it's most needed, your eyes have a high concentration of Mitochondria which are hindered from working optimally by reactive oxygen species (ROS) that accumulate in your eyes. In the same way that you produce waste that you need to poop out in the bathroom, your mitochondria produce toxic waste, the ROS that needs to be detoxed and flushed out by antioxidants.

Visomitin feels mostly like normal eye drops, it doesn't have an immediate effect on improving vision but it did make my eyes feel better after a long day of working; staring at my computer screen. My wife would often remind me to take it if my eyes were a bit red and strained which would restore my vision a bit and keep my eyes from getting too dry.

I had my vision checked by an ophthalmologist before I started using Visomitin and I had it checked again recently after using it for about 6 months. The good news is that my vision had not gotten worse, it was the same as before.

I use this type of biohack for prevention, not hoping to cure anything. My vision is already a bit of a challenge, my career as an internet entrepreneur long-term is deleterious to my eyesight and I see this sort of Mitochondrial technology as a worthwhile preventative measure especially considering the very reasonable cost of a little bottle of Visomitin; $19 - $33. I used it a little less frequently than prescribed for the vision conditions it's supposed to treat and four bottles lasted me 6 months.

Mitochondria and Eye Related Disease

From Dr. Lee Know's recent book

As we age , we’re at a higher risk of developing age - related eye diseases , and we might predict that these conditions have mitochondrial components to them . These conditions include age - related macular degeneration , cataract , glaucoma , diabetic eye disease , and others . (1947-1949)

the retina requires proportionally more energy ( per cell ) than any other tissue in the body , and the retina is also where the density and number of mitochondria per cell are among the highest found in the body .(1958-1959)

We suggest you read this article about the fascinating mechanism of action and history of SkQ1...

SKQ1

Category: Nootropic Ingredients

Visomitin SkQ1 works on a cellular level by reducing damage caused by excessive reactive oxygen species (ROS), which are types of free radicals that play an important role in cell signaling.

SkQ1 also selectively protects the membrane’s cardiolipin from oxidation and by doing so prevents mitochondrial dysfunction and the process of cell death called apoptosis. Another feature of the compound is that its oxidation chemistry allows it to be recycled in the mitochondria, creating a renewable antioxidant. The company has built its clinical development program to leverage SkQ1 across age-related disorders that could include treating neurodegenerative diseases like Parkinson’s and Alzheimer’s.

SkQ1 was developed as an agent fighting a spectrum of age-related diseases at their root, which in our hypothesis is oxidative stress inside mitochondria,” Natalia Perekhvatova, Mitotech’s chief executive, said. “In case of Dry Eye Disease our ophthalmic solution Visomitin has been shown not only to suppress inflammation, but also to protect corneal and conjunctival cells from damage and to promote health of lacrimal glands, therefore addressing the disease from multiple angles.

On-label indications:

• Dry eye syndrome
• Initial stage of age-related cataract
• Cataracts and glaucoma, including their most bad choices
• Uveitis
• Enteral inflammations
• Neurodegeneration

Scientific Research

It's the subject of 4 studies on Pubmed and is currently undergoing a Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study. In 2015, it passed a Phase 2 trial, where 240 patients were given a 6-week course of Visomitin, it concluded:

Based on the results of this study, Visomitin is effective and safe for use in eye patients with [dry eye syndrome] for protection from corneal damage.

SkQ1- a cardiolipin peroxidation inhibitor

A few years ago a small molecule SkQ1 was synthesized at Moscow State University. One part of SkQ1 functions as a molecular “tow truck”, carrying the other part of the molecule – an extremely active antioxidant plastoquinone – into mitochondria. SkQ1 has been shown to accumulate in mitochondria in an extremely targeted and efficient manner. The physics of the mitochondrial membrane and the unique properties of SkQ1 direct it into the inner leaflet of the inner mitochondrial membrane with incredibly high precision. The molecule was designed to act as a mitochondria-targeted ROS scavenger in general and as a very efficient cardiolipin peroxidation inhibitor in particular

Mitotech’s program for the treatment of Dry Eye Disease is focused on Visomitin, which is approved in Russia and had a successful Phase II study in the U.S. that indicated a statistically significant effect of SkQ1 on both signs and symptoms of dry eye.